Comparison of the effectiveness of topical silicone gel and corticosteroid cream on the pfannenstiel scar prevention — a randomized controlled trial by Meseci, Elif et al.
591
ORIGINAL PAPER /  GYNECOLOGY
Ginekologia Polska
2017, vol. 88, no. 11, 591–598
Copyright © 2017 Via Medica
ISSN 0017–0011
DOI: 10.5603/GP.a2017.0107
Comparison of the effectiveness of topical silicone 
gel and corticosteroid cream on the pfannenstiel scar 
prevention — a randomized controlled trial
Elif Meseci1, Semra Kayatas2, Murat Api3, Aysen Boza4, Muzaffer Seyhan Cikman2
1Department of Obstetrics and Gynecology, Acıbadem Kozyatagı Hospital, Istanbul, Turkey 
2Department of Obstetrics and Gynecology, Zeynep Kamil Maternity and Children’s Diseases Training 
and Research Hospital, Istanbul, Turkey 
3Department of Obstetrics and Gynecology, Faculty of Medicine, Medipol University, Istanbul, Turkey 
4Department of Obstetrics and Gynecology,VKV American Hospital, Istanbul, Turkey
ABSTRACT
Objectives: To compare the effects of topical silicone gel and corticosteroid cream for preventing hypertrophic scar and 
keloid formation following Pfannenstiel incisions.
Material and methods: Fifty patients operated for benign gynecological diseases through primary Pfannenstiel incision 
were included. The wounds were randomly allocated to the treatment and control arms. In the treatment arm, the wounds 
were divided into two halves; one was treated with silicone gel and the other with methylprednisolone cream. No treat-
ment was administered to the control group. Scars using the modified Vancouver Scar Scale (MVSS), patient satisfaction, 
and side effects were evaluated before and after (3rd month when treatment discontinued and 6th month) the treatment.
Results: Thirty-nine patients (21 patients in the treatment group and 18 patients in the control group) completed the stu-
dy. Intragroup comparisons of the 3rd month and 6th month scores of the MVSS revealed that the scores of all parameters 
(height, pigmentation, vascularity, pliability, and total MVSS score) significantly decreased at the 6th month evaluation as 
compared with the 3rd month evaluation in all groups (control, silicone, and methylprednisolone groups). Multiple group 
comparisons at the 6th month revealed that the most prominent improvements occurred in the methylprednisolone group 
in all MVSS parameters as compared with the control group and in the height, vascularity, and pigmentation parameters 
as compared with the silicone group. No side effects were experienced by the patients with either treatment and patient 
satisfaction was higher in the methylprednisolone group. 
Conclusion: The use of topical methylprednisolone cream in fresh wounds at the postoperative early period appears to 
be promising.
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INTRODUCTION
Skin incisions may result in scar formation. Pathological 
cutaneous scars such as keloids and hypertrophic scars 
(HS) occur due to general failure of normal wound healing 
processes. These scars are usually characterized by inflam-
mation, excessive fibroblast proliferation, and abnormal 
deposition of extracellular matrix proteins [1]. Both HS and 
keloids usually develop within 1 to 3 months after an injury, 
trauma, or surgical incision [2].
Several treatments and prophylactic modalities including 
surgical excision, radiation, pressure therapy, cryotherapy, 
topical silicone gel, intralesional injections of corticosteroids, 
laser treatment, and various medications have been used in 
the management of HS and keloids [3–6]. Silicone gel sheet-
ing and intralesional cortisone injection have been suggested 
as effective prevention and treatment of HS and keloids [7, 
8]. Recent studies offer that topical agents might be effective 
first-line options for non-invasive treatment of these scars [9].
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OBJECTIVES
The aim of this study was to compare the effectiveness 
of topical silicone gel and topical corticosteroid cream for 
preventing postoperative HS and keloids resulting from 
Pfannenstiel incision following gynecological operations.
MATERIAL AND METHODS
The present prospective, randomized, controlled study 
was conducted between January 2014–December 2014 in 
Zeynep Kamil Maternity and Children’s Diseases Training and 
Research Hospital, Istanbul, Turkey. This study followed the 
Declaration of Helsinki and was approved by Ethics Com-
mittee of our hospital. All patients were informed about the 
study and provided written consents. 
Fifty patients undergone operation for benign gynecolo-
gical diseases through a primary Pfannenstiel incision were 
included. These patients aged 28–52 years and had Fitzpa-
trick skin type II–V. The wound closures were performed 
using the same procedure by the same surgeon. Patients 
with a history of HS or keloids, those having any previous 
abdominal incisions, systemic infection, patients having 
chronic medical illnesses that might affect wound healing 
(diabetes mellitus, renal failure, hematological diseases), 
a known hypersensitivity/allergy to any medication used in 
the study, those using certain systemic treatments within 
the last 6 months (such as cortisone, anti-inflammatory 
drugs) were excluded from the study.
After confirming normal epithelialization and wound 
healing on the incision site at the 10th postoperative day, 
patients who met the selection criteria were randomised 
to the treatment group or control group. In the treatment 
group (n = 25), the wound was divided into two halves; one 
half was treated with silicone gel (Dermatix®; Hanson Medi-
cal Inc., Kingston, WA, USA) and the other half with methyl-
prednisolone cream (Advantan®; Intendis GmbH, Germany). 
Silicone gel was applied twice a day and the corticosteroid 
cream in every other 2 days to prevent skin atrophy. The 
treatment duration was 3 months. No treatment was admin-
istered to the control group (n = 25). Funding was supported 
by the researchers on their own. A blinded dermatologist 
performed the follow-up examinations before treatment (at 
baseline, i.e., at the 10th postoperative day), after treatment 
(at the end of the 3rd month), and 3 months after discontinu-
ation of treatment (at the end of the 6th month). During the 
follow-up period, 4 patients from the treatment group and 
7 patients from the control group dropped out because 
of personal reasons. Finally, 39 patients (21 patients in the 
treatment group and 18 patients in the control group) were 
analyzed at the end of the 6th-month follow-up period.
Scar assessment was performed using the modified 
Vancouver Scar Scale (MVSS) by assessing scar pigmenta-
tion (0 — normal color, 1 — hypopigmentation, 2 — hy-
perpigmentation), vascularity (0 — normal color, 1 — pink, 
2 — pink to red, 3 — red, 4 — red to purple, 5 — purple), 
pliability (0 — normal, 1 — supple, 2 — yielding, 3 — firm, 
4 — banding-rope tissue, 5 — contracture), and height 
(0 — normal/flat, 1: < 2 mm, 2: 2–5 mm, 3: > 5 mm) [10]. 
In the present study, a linear probe ultrasound (Mindray 
DC6, 5.0–7.5 mHz, China) was used to measure the scar 
thickness. A blinded radiologist performed the assessments.
In the present study, the side effects experienced by the 
patients were also assessed every 2 months. At the 6-month 
follow-up, the patients were asked to rate their satisfaction 
using a 4-point grading scale (1 = unsatisfied, 2 = slightly 
satisfied, 3 = satisfied, 4 = very satisfied) for each group.
Statistical analysis
All statistical analyses were performed using SPSS 
Statistics for Windows, version 20.0. (IBM Corp., Armonk, 
NY, USA). Data are expressed as mean, standard deviation, 
median and 25th (Q1) and 75th (Q3) percentiles. For non-
-normally distributed variables, two group comparisons 
were performed using the Mann-Whitney U test. Multiple 
group comparisons of non-normally distributed data were 
performed using the Kruskal-Wallis test, which was followed 
by post hoc analysis. Moreover, Wilcoxon signed-rank test 
was used to compare the 3rd and 6th month values. A p value 
of < 0.05 was considered statistically significant.
RESULTS
In the present study, 39 patients were analyzed. The 
patient flowchart is presented in Figure 1. Comparison of 
age and body mass index (BMI) values and scar assessment 
scores based on MVSS at baseline between the control and 
treatment groups are presented in Table 1. There was no 
significant difference between the control and treatment 
groups regarding age, BMI values, and MVSS scores. All pa-
tients (n = 39) underwent a laparotomy with gynecological 
indications. These interventions were total abdominal hys-
terectomy + bilateral salpingo-oophorectomy(TAH + BSO) 
in 61%, only TAH in 22%, and myomectomy in 16.7% in 
the control group and TAH + BSO in 57%, only TAH in 33%, 
myomectomy in 4.8%, and salpingectomy in 4.8% in the 
treatment group.
Intragroup comparisons of the 3rd month and 6th month 
scores of the MVSS revealed that the scores of all parameters 
(height, pigmentation, vascularity, pliability, and total MVSS 
score) significantly decreased at the 6th month evaluation 
as compared with the 3rd month evaluation in all groups 
(control, silicone, and methylprednisolone groups) (Table 2). 
Multiple group comparisons revealed that while there 
were no significant differences among the three groups in 
terms of the MVSS scores in any of the parameters at the 
3rd month evaluation, the MVSS scores of all parameters 
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significantly differed among the groups at the 6th month 
evaluation (p < 0.05 for all; Table 2). Accordingly, subgroup 
analyses performed for the 6th month evaluations demon-
strated that the height and vascularity scores of the methyl- 
prednisolone group was significantly lower than those of the 
control and silicone groups (p = 0.002 and p = 0.043, respec-
tively for height parameter and p = 0.014 and p = 0.047 for 
vascularity parameter). The pliability and total MVSS scores 
of the silicone and methylprednisolone groups were signifi-
cantly lower than those of the control group (p = 0.026 and 
p = 0.022 for the pliability parameter and p = 0.049 and 
p = 0.002 for the total MVSS score). Moreover, the pigmen-
tation score of the methylprednisolone group was signifi-
cantly lower than those of the control and silicone groups 
(p = 0.001 and p = 0.197, respectively). The pigmentation 
score of the silicone group was also significantly lower 
than that of control group (p = 0.022).
Changes in the scar scores assessed by the MVSS be-
tween the 3rd and 6th months in the study groups and 
their comparisons are presented in Table 3 and also in 
Figure 2. Multiple comparisons of the groups revealed that 
the change in the MVSS scores significantly differed among 
the three groups in all parameters (p < 0.05), except for the 
pigmentation parameter. Accordingly, subgroup analyses 
demonstrated significantly higher change in height score 
in methylprednisolone group than in the control and sili-
cone groups (p = 0.0001 and p = 0.024, respectively). The 
change in the height score was also significantly higher in 
the silicone group than in the control group (p = 0.041). The 
change in the vascularity score was significantly higher in 
the methylprednisolone group than in the control group 
Table 1. Comparison of age, body mass index values, and scar 
assessment scores based on the modified Vancouver Scar Scale 
between the control and treatment groups before the treatment 
(at the 10th postoperative day)
Control group
(n = 18)
Treatment group
(n = 21) p
Age (years) 43.44 ± 5.99 44.5 (42–48)
44.05 ± 4.57 
45 (42–47) 0.777
BMI [kg/m2] 25.4 ± 3.2924.3 (2)
24 ± 2.98
23.7 (2) 0.64
MVSS
Height 0.33 ± 0.49 0 (0–1)
0.38 ± 0.50 
0 (0–1) 0.760
Pigmentation 1.22 ± 0.94 2 (0–2)
1.38 ± 0.86 
2 (1–2) 0.608
Vascularity 2.89 ± 0.58 3 (3–3)
2.86 ± 0.65 
3 (2–3) 0.845
Pliability 1.50 ± 0.51 1.5 (1–2)
1.38 ± 0.50 
1 (1–2) 0.461
Total score 5.94 ± 1.06 6 (5–7)
6.00 ± 0.95 
6 (5–7) 0.976
All data are presented as mean ± standard deviation and median (Q1–Q3); 
BMI — body mass index, MVSS — modified Vancouver Scar Scale
Enrollment
Allocation
Follow-up
Analysis
Assessed for eligibility (n = 61)
Excluded (n = 11)
• Not meeting inclusion criteria (n = 11)
• Declined to participate (n = 0)
Randomized (n = 50)
Allocated to intervention (n = 25)
• Received allocated intervention (n = 11)
• Did not receive allocated intervention (n = 0)
Allocated to control (n = 25)
• Received allocated intervention (n = 25)
• Did not receive allocated intervention (n = 0)
Analysed (n = 21)
• Excluded from analysis (n = 0)
Analysed (n = 18)
• Excluded from analysis (n = 0)
Lost to follow-up (personal reasons) (n = 4)
Discountinued intervention (n = 0)
Lost to follow-up (personal reasons) (n = 7)
Discountinued intervention (n = 0)
Figure 1. Patient flowchart
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(p = 0.004). The changes in the pliability and total scores of 
the methylprednisolone and silicone groups were signifi-
cantly higher than that of the control group (p = 0.016 and 
p = 0.01, respectively for pliability and p = 0.001 and 
p = 0.022 for total score). There were no significant dif-
ferences between the silicone and methylprednisolone 
groups in terms of the changes in the vascularity, pliability, 
and total MVSS score (p = 0.219, p = 0.885, and p = 0.167, 
respectively).
Figure 3 shows the appearance of the scar from each 
group at baseline, at the end of the 3rd and 6-months. None 
of the patients experienced side effects during treatment 
period.
Evaluation of the patient satisfaction at the 6th month 
follow-up revealed similar satisfaction scores in methylpred-
nisolone and silicone groups (3.33 ± 0.73 [median, 3, Q1–Q3, 
3–4] and 2.95 ± 0.87 [median, 3, Q1–Q3, 2–4], respectively; 
p = 0.116). In the present study, 11% of the patients in the 
control group, 33% of the patients in the silicone group, 
and 48% of the patients in the methylprednisolone group 
were very satisfied. The rate of patient satisfaction was sig-
nificantly higher in the methylprednisolone group than in 
the control group (p = 0.001). No significant difference was 
found in terms of patient satisfaction between the control 
and silicone groups (p = 0.21) and between the silicone and 
methylprednisolone groups (p = 0.05) (Table 4).
Table 2. Scar assessment scores based on the modified Vancouver Scar Scale at the 3rd and 6th month follow-ups in the study groups and their 
comparisons
Groups
Control
(n = 18)
Silicone
(n = 21)
Methylprednisolone
(n = 21)
Mean ± SD 
Median (Q1–Q3)
Mean ± SD 
Median (Q1–Q3)
Mean ± SD 
Median (Q1–Q3) p p1 p2 p3
Height
3rd month 1.44 ± 0.78 1.5 (1–2)
1.43 ± 0.6 
1 (1–2)
1.52 ± 0.51 
2 (1–2) 0.908 — — —
6th month 1.17 ± 0.62 1 (1–2)
0.86 ± 0.73 
1 (0–1)
0.48 ± 0.68 
0 (0–1) 0.008 0.161 0.002 0.043
p 0.025 0.0001 0.001
Pigmentation
3rd month 2.33 ± 0.97 3 (1.75–3)
1.9 ± 0.7 
2 (1–2)
1.76 ± 0.77 
2 (1–2) 0.059 — — —
6th month 1.78 ± 0.94 2 (1–2.25)
1.05 ± 0.97 
1 (0–2)
0.67 ± 0.8 
0 (0–1) 0.003 0.022 0.001 0.197
p 0.004 0.001 0.0001
Vascularity
3rd month 2.22 ± 0.88 2.5 (1–3)
2.38 ± 0.81 
3 (2–3)
2.19 ± 0.81 
2 (1.5–3) 0.706 — — —
6th month 1.72 ± 0.96 2 (1–2.25)
1.52 ± 1.17 
2 (0–2.5)
0.95 ± 0.87 
1 (0–1.5) 0.048 0.639 0.014 0.047
p 0.003 0.001 0.0001
Pliability
3rd month 1.89 ± 0.9 2 (1–3)
1.67 ± 0.86 
2 (1–2)
1.62 ± 0.81 
2 (1–2) 0.561 — — —
6th month 1.56 ± 0.78 2 (1–2)
0.95 ± 0.81 
1 (0–2)
0.9 ± 1 
1 (0–1.5) 0.035 0.026 0.022 0.670
p 0.014 0.001 0.001
Total score
3rd month 7.61 ± 2.99 9 (5–10)
7.29 ± 2.19 
8 (5.5–9)
6.95 ± 2.33 
7 (5.5–9) 0.523 — — —
6th month 6.11 ± 2.74 6.5 (4.75–8.25)
4.29 ± 2.97 
5 (1–7)
3 ± 2.81 
3 (0.5–4) 0.006 0.049 0.002 0.136
p 0.0001 0.0001 0.0001
SD — standard deviation, Q1 — 25th percentile, Q3 — 75th percentile; p1 — control group vs. silicone group; p2 — control group vs. cortisone group; p3 — silicone 
group vs. cortisone group
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DISCUSSION
Wound healing includes several steps, consisting of 
the inflammatory, tissue-formation, and tissue-remodeling 
phases [11]. To date, fibroblast activity, extracellular matrix 
components, growth factors, cytokines, and other mechani-
sms have been investigated as possible factors responsible 
for scar formation [12].
In this study, we evaluated the uses of topical silicone 
gel and corticosteroid cream versus no treatment for pre-
venting surgical scar formation in terms of both efficacy 
and convenience. We preferred topical administration of 
corticosteroids in cream form to decrease any potential side 
effects and used the same route for silicone gel and cortico-
steroid cream for comparison. In addition, we thought that 
we could enhance patient compliance with a noninvasive, 
painless, and easily applied treatment.
Various mechanisms have been proposed as possible 
modes of action for silicone-based agents and corticoste-
roids in the wound healing processes including: 1) an incre-
ased temperature or oxygen tension increasing collagenase 
activity and leading to collagen breakdown shrinking the 
scars [3, 7], 2) occlusion and hydration of wounds [7, 13]; 
reduction in transepidermal water loss decreases stimula-
tion of keratinocytes which stops cytokine production [13], 
and 3) polarization of the scar tissue caused by a negative 
static charge between silicone and skin [14] and the modu-
lation of growth factors [9, 15, 16]. 
Several studies have suggested topical silicone gel to 
be the first-line option for prevention of HS and keloids [7, 
15–17]. In the study by Chan et al. [7] of 50 patients, sternal 
wounds were divided into two halves; one half was treated 
with silicone gel and the other half with placebo gel for 3 mon-
Table 3. Changes (decreases in percentages) in the scar assessment scores based on the modified Vancouver Scar Scale between the 3rd and 6th 
months in the study groups and their comparisons
Groups
Change (%) in the MVSS 
scores between 3rd and 
6th months
Control
(n = 18)
Silicone
(n = 21)
Methylprednisolone
(n = 21)
Mean ± SD
Median (Q1–Q3)
Mean ± SD
Median (Q1–Q3)
Mean ± SD
Median (Q1–Q3) p p1 p2 p3
Height 12.96 ± 21.8110 (0–37.5)
40.48 ± 43.64
50 (0–100)
71.43 ± 40.53
100 (50–100) 0.001 0.041 0.0001 0.024
Pigmentation 44.44 ± 29.750 (25–66.67)
55.56 ± 38.85
50 (16.67–100)
68.25 ± 40.79
100 (41.67–100) 0.129 — — —
Vascularity 25.93 ± 32.9516.67 (0–37.5)
45.24 ± 41.21
33.33 (0–100)
59.52 ± 35.58
66.67 (33.33–100) 0.021 0.147 0.004 0.219
Pliability 15.74 ± 27.110 (0–33.33)
46.83 ± 40.7
50 (0–100)
49.21 ± 44.87
50 (0–100) 0.019 0.01 0.016 0.885
Total score 24.89 ± 29.5414.29 (10–34.09)
46.85 ± 35.93
36.36 (22.22–90)
60.15 ± 29.69
57.14 (36.67–87.5) 0.002 0.022 0.001 0.167
MVSS — modified Vancouver Scar Scale; SD — standard deviation; Q1 — 25th percentile; Q3 — 75th percentile; p1 — control group vs. silicone group; p2 — control 
group vs. cortisone group; p3 — silicone group vs. cortisone group.
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Figure 2. Changes (decreases in percentages) in the scar scores assessed by the modified Vancouver Scar Scale (MVSS) between the 3rd and 6th 
months
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ths. In that study, silicone gel was associated with a significant 
reduction in the scores for scar pigmentation, vascularity, 
pliability, height, pain, itchiness (p ≤ 0.02), assessed by Van-
couver Scar Scale(VSS), and it was suggested as promising in 
preventing HS. In a recent study, Medhi et al. [18] investigated 
the efficacy of silicone gel in patients (n = 36) with recent sur-
gical scars. After 3 months of treatment, significant improve-
ments were observed in the height, pliability, and vascularity 
parameters (p = 0.015, p = 0.031, p = 0.031, respectively). 
Additionally, the investigator was completely satisfied with 
the scar healing in 71.4% patients. In a study by Kong et al. 
[19], efficacy of topical silicone gel treatment on the surgical 
wounds of patients (n = 100) undergoing total knee arthro-
plasty was investigated. Postoperative 3 months, 6 months 
and  1 year evaluations revealed no significant difference 
between the silicone and placebo gel groups regarding VSS 
components at the postoperative 3rd month, only pigmenta-
tion and height components were significantly lower in the 
silicone gel group than placebo gel group at postoperative 
6 months and 1 year. In our study, MVSS scores of all parame-
ters were reduced at the 6th month evaluation as compared to 
the 3rd month in silicone group. While there was no significant 
difference between the control and silicone groups in any 
MVSS parameter at the 3rd month evaluation, it was observed 
that the pigmentation, pliability, and total MVSS scores were 
significantly lower in silicone group than in the control group 
at the 6th month evaluation. When evaluated regarding the 
changes in MVSS scores between the 3rd and 6th months in 
the study groups, the changes in the height, pliability, and 
total MVSS scores were significantly higher in silicone group 
than in the control group.
The severity of inflammation and type of immune respon-
se predisposes individuals to excessive scar formation [1]. 
The effects of corticosteroids are mainly owing to their sup-
pressive effects on the inflammatory process and also due 
to decreases in collagen and glycosaminoglycan synthesis 
and increases in collagen and fibroblast degeneration [20]. 
Intralesional corticosteroid injection is widely accepted for 
the management of HS and keloids [3–6, 8]. The injection 
causes reductions in the scar volume and results in an impro-
vement in the scar pliability, height, and symptoms. Owing 
to poor tissue absorption, intralesional injections are prefer-
red in mature scars [21]. Intralesional corticosteroid injection 
is recommended at the end of 6 months for patients with 
postoperative linear scars who fail to respond to prophy-
lactic treatments in the first 6 months postoperatively and 
having ongoing HS [5, 6, 22–24]. In the present study, ho-
wever, instead of intralesional corticosteroid injection, we 
aimed to evaluate a novel approach in which a corticosteroid 
in cream form was used in fresh wounds at the postopera-
tive early period when absorption is good. To the best of 
our knowledge, this is the first study to compare the use 
Table 4. Evaluation of patient satisfaction at the end of the 6th month
 Control group
(n = 18)
Silicone group
(n = 21)
Methylprednisolone group
(n = 21) p1 p2 p3
Satisfaction, n (%)
Unsatisfied 0 1 (5) 1 (4)
0.21 0.001 0.05
Slightly satisfied 7 (39) 5 (24) 0
Satisfied 9 (50) 8 (38) 10 (48)
Very satisfied 2 (11) 7 (33) 10 (48)
p1 — control group vs. silicone group; p2 — control group vs. cortisone group; p3 — silicone group vs. cortisone group
Figure 3. A. Appearance of the scar on the 10th postoperative day 
of a patient in the (a) control group and (b) treatment group. Note 
the red to purple, hyperpigmented appearance; B. Appearance of 
the scar at the end of the 3rd month of a patient in the (a) control 
group and (b) treatment group; C. Appearance of the scar at the 
end of the 6th month of a patient in the (a) control group and (b) 
treatment group. Note that the better external appearance, the 
decreased erythema and reduced irregular texture are distinct in the 
methylprednisolone cream applied side. M — methylprednisolone 
cream applied side and S — silicone gel applied side
A
B
C
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of methylprednisolone in topical cream form with topical 
silicone gel in the early postoperative period regarding scar 
prevention and patient satisfaction.
According to a Cochrane Collaboration Review in 2013, 
no prevention studies were identified comparing silicone 
gel treatment and cortisone injection for preventing HS 
and keloids [25]. However, three studies comparing these 
products on the treatment arm were identified [26–28]. In 
their prospective randomized trial, Sproat et al. [26] treated 
one half of the hypertrophic sternal scars of 14 patients with 
triamcinolone acetonide injection and the other half with 
silicone gel sheets. They reported decreased scar height 
in both groups but an increase in scar width. The authors 
reported that the silicone gel sheets are associated with 
earlier symptomatic relief, a more esthetic scar appearance. 
However, participants in the triamcinolone injection group 
experienced complications, including pain, skin atrophy, 
pigmentary changes. Accordingly, they suggested silicone 
gel as treatment of choice for symptomatic HS. In the study 
by Tan et al. [27], 16 of 17 patients treated with intralesional 
injections of triamcinolone acetonide had a significant re-
duction in the size of keloids and thus the authors suggested 
this method as the primary treatment for keloids. Kelemen 
et al. [28] reported that the intralesional steroid injection 
led to a greater improvement of MVSS as compared to the 
silicone gel. In the present study, it was observed that the 
scores of all MVSS parameters were significantly reduced in 
methylprednisolone group at the 6th month evaluation as 
compared to the 3rd month. While there was no significant 
difference between methylprednisolone and control groups 
in any MVSS parameter at the 3rd month evaluation, the sco-
res of all MVSS parameters at the 6th month evaluation were 
significantly lower in methylprednisolone group than in the 
control group. Additionally, evaluation of the changes in 
MVSS scores between the 3rd and 6th months also revealed 
that the decreases in all scores of MVSS parameters were 
significantly higher in methylprednisolone group than in the 
control group. Comparison of the methylprednisolone and 
silicone groups at the 6th month evaluation revealed that 
the scores of height, pigmentation, and vascularity para-
meters of the methylprednisolone group were significantly 
lower in the silicone group. On the other hand, evaluation 
of the changes in the MVSS scores between the 3rd and 6th 
months revealed that only the change in the height score 
was significantly higher in the methylprednisolone group 
than in the silicone group. In contrast to intralesional corti-
costeroid injection, none of the patients in treatment groups 
experienced side effects during the treatment.
Silicone gel treatment has been successfully employed 
for prevention of HS and keloid formation on different parts 
of the body [7, 18, 28, 29]; however, it was not very effective 
on the Pfannenstiel incisions in our study. This could be due 
to the incision site at which HS and keloid formations are 
less common than in the other parts of the body. 
In the present study, patient satisfaction with the treat-
ments was also evaluated at the 6th month. It was observed 
that the patients in silicone group were “very satisfied” by 33%, 
the patients in methylprednisolone group were “very satis-
fied” by 48%, and the patients in the control group were “very 
satisfied” by 11%. In the study by Medhi et al. [17], the rate 
of patients who were “completely satisfied” or “satisfied” with 
the treatment was 54%. Sepehrmanesh [30] reported that 
69.8–85% of the patients rated the improvement by silicone 
gel as “good” or “very good”. In the present study, the rate of 
satisfaction was significantly higher in methylprednisolone 
group than in the control group (p = 0.001). We believe that 
patients did not experience any side effect related to methyl-
prednisolone cream and did not feel height and/or swelling 
at the site of incision might positively affect their satisfaction.
There are many factors that may contribute to scar over-
growth [14]. In this study, we attempted to eliminate these 
variables by choosing the same anatomical region of the 
same participant for treatments. Moreover, we also ensured 
using the same materials by the same surgeon and elimi-
nated any surgeon-related risk factors for wound healing.
The present study has some limitations. First, it was im-
possible to exactly monitor how the patients used the gel or 
cream on their wounds. Second is the small sample size and 
relatively short duration of treatment despite no definitive 
treatment duration in the literature. On the other hand, 
the strength of this study is that the study was designed as 
a prospective study and that evaluation of the same wound 
may eliminate the possibility of wound healing differences 
that could occur depending on the patients. 
CONCLUSIONS 
We demonstrated that there was no significant differen-
ce regarding the side effects and efficacy of the silicone gel 
and methylprednisolone cream. In addition, both agents in 
comparison failed to exhibit superiority over each other for 
preventing scar formation. However, the most prominent 
improvements occurred in the methylprednisolone group 
in all MVSS parameters as compared with the control group 
and in the height, vascularity, and pigmentation parameters 
as compared with the silicone group. Furthermore, patient 
satisfaction rate was higher also in the methylprednisolone 
group. In this context, the use of a topical methylpredniso-
lone cream appears to be promising. Therefore, we believe 
that randomized controlled trials with larger sample sizes 
and longer follow-up periods are required.
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